Agro Phos (India) Limited Overview
Agro Phos (India) Limited is an Indore-based, promoter-controlled micro-cap manufacturer of Single Super Phosphate (SSP), the simplest and cheapest phosphatic fertiliser in India's Nutrient-Based Subsidy (NBS) system. With two plants in Madhya Pradesh — Dewas (45,000 MTPA) and Meghnagar, Jhabua district (115,000 MTPA), for a combined 160,000 MTPA — it is a small, regional, single-product player in a fragmented SSP industry dominated by larger integrated producers such as Khaitan Chemicals & Fertilizers, Rama Phosphates, Madhya Bharat Agro Products and Coromandel International. SSP accounted for roughly 85–90% of sales over FY2023–FY2025 and about 99% in 9MFY2026. The company sells through its own network of 200+ dealers across six states and, increasingly, through bulk off-take memoranda with public-sector and national marketers (Indian Potash, HURL, RCF, Matix, MAIDC, BVFCL). Its economics are dictated by government subsidy rates, imported rock-phosphate costs, monsoon quality and working-capital intensity rather than by brand or technology.
What the company does
Agro Phos manufactures phosphatic and allied fertilisers and trades complementary fertilisers. Its manufactured portfolio, as described in exchange filings and CARE Ratings' rationale, consists of Single Super Phosphate (SSP), Nitrogen-Phosphorus-Potassium (NPK) mixtures, Zinc Sulphate, Phosphate Rich Organic Manure (PROM), Potash Derived from Molasses (PDM), organic manure, and Calcium Sulphate (sold as soil conditioner / gypsum). It also trades Di-Ammonium Phosphate (DAP), Urea, Ammonium Sulphate and other fertilisers opportunistically, depending on customer demand and market conditions. Historically the company also reported a minor "Others" activity (commodity trading), but in its latest quarterly integrated filings (Q2 FY2026) it declares a single reportable segment: Fertilisers.
Company's own description (paraphrased from annual report and filings)
The company describes itself as an ISO 9001:2008-certified fertiliser manufacturer whose Dewas and Meghnagar facilities are equipped with machinery, cranes, conveyor belts and handling equipment for smooth processing and logistics, with a fully integrated process running from raw-material procurement through final testing and bagging for direct farmer use. It packs product in "gazette" bags it describes as easy to handle and stack, and it operates an in-house testing laboratory to check product against quality standards under the Fertiliser (Control) Order, 1985.
Business model and revenue model
| Revenue stream | Nature | Approx. share | Source / basis |
|---|---|---|---|
| Manufactured fertiliser sales (SSP dominant, plus NPK, ZnSO4, PROM, PDM, gypsum) | Product sale; realisation = farm-gate MRP net of trade margins + government NBS subsidy on SSP/NPK credited to manufacturer after point-of-sale verification | ~91% of net sales FY2025 (~90% FY2024) | CARE Ratings, 31-Mar-2026 |
| Traded fertilisers (DAP, Urea, Ammonium Sulphate, others) | Merchant trading, low margin | ~9% FY2025 (~10% FY2024) | CARE Ratings, 31-Mar-2026 |
| Services / subscription / licensing | — | 0% | — |
The revenue model is purely product-based. A material portion of each tonne's realisation is the government subsidy, which is paid with a lag; this is why the company's receivables, working-capital borrowings and liquidity swing with subsidy-release timing. CARE notes that FY2025 sales growth was driven by higher subsidy rates and volumes (manufacturing volumes +~5%, realisations +~6%).
Value-chain position
Agro Phos sits in the conversion stage of the phosphate chain: it buys imported rock phosphate (mainly from Egypt and Jordan, per CARE) and locally sourced sulphuric acid, acidulates the rock to produce SSP (≈16% P2O5 water-soluble plus sulphur and calcium), then bags and distributes. It is not backward-integrated into sulphuric acid or phosphoric acid (unlike larger peers such as Khaitan, Rama and Madhya Bharat Agro, which own acid plants), and it has no captive rock source. Historically, the Government of India told Parliament that Rajasthan State Mines and Minerals Ltd (RSMML) was the company's indigenous rock-phosphate source; current sourcing is predominantly import-based per CARE.
Customer types and end-markets
| Customer type | Description |
|---|---|
| Dealers / distributors / retailers | 200+ dealers across Maharashtra, Madhya Pradesh, Rajasthan, Uttar Pradesh, Chhattisgarh and Andhra Pradesh (CARE, Mar-2026) |
| Institutional marketers (bulk off-take) | Indian Potash Ltd (IPL), Hindustan Urvarak & Rasayan Ltd (HURL), Rashtriya Chemicals & Fertilizers (RCF), Matix Fertilisers & Chemicals, Maharashtra Agro Industries Development Corporation (MAIDC), Brahmaputra Valley Fertilizer Corporation (BVFCL) |
| Government (indirect) | Department of Fertilizers pays NBS subsidy; state governments license manufacturing and enforce quality |
| End users | Indian farmers — particularly oilseed (soybean, mustard, groundnut), pulse and cereal growers in central India, where SSP's sulphur content is valued |
Independent characterisation
Agro Phos is best understood as a subsidy-dependent, working-capital-heavy, single-product commodity converter of sub-scale size (revenue ≈ INR 148 Cr in FY2026, roughly one-sixth of Rama Phosphates and one-thirteenth of Madhya Bharat Agro). Its competitive edge is local: proximity to central-Indian SSP demand, a long-standing promoter presence, and the ability to run plants for institutional marketers who need SSP volume without building capacity. Its structural weaknesses — no acid integration, no captive raw material, almost full utilisation of bank working-capital lines, and earnings that swing between losses (FY2024) and modest profits — mean its returns on capital are cyclical and low on a multi-year average (3-year average ROE ≈ 3% per Screener.in). Strategically, the company has tilted from dealer-led branded retail toward contract manufacturing/off-take for national marketers, which raises volume visibility but caps pricing power.
Strategy
Stated strategy (themes)
The company does not publish investor presentations, hold earnings calls or issue medium-term guidance. Strategic themes are inferred from Directors' Reports, Regulation 30 disclosures and CARE's discussions with management:
-
Volume assurance through institutional off-take — repeated MoUs with public-sector and national marketers (IPL, HURL, RCF, MAIDC, BVFCL, Matix) to keep 160,000 MTPA of capacity loaded.
-
SSP-centric portfolio with value-added variants — "Krishi Samridhi" variant SSP, PROM, PDM and gypsum to broaden the basket around the core SSP line.
-
Inorganic expansion attempts — the 2025 Bharat Phosphates & Chemicals acquisition (withdrawn) and the earlier Shri Tulsi Phosphate investment (now largely exited).
-
Capital discipline / shareholder return — first meaningful dividend (INR 1.00) paid for FY2025.
-
Circular raw materials — PDM made from distillery spent-wash ash (Som Distilleries MoU).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Type | Status / outcome |
|---|---|---|---|
| 28 May 2024 (context) | HURL MoU for 125,350 MT SSP | Off-take partnership | Term ended 27 May 2025; renewal not disclosed |
| 16 Jul 2025 | Acquisition of Bharat Phosphates & Chemicals Pvt. Ltd. business undertaking (≤ INR 3 Cr) as WOS | M&A | Withdrawn 29 May 2026 |
| 06 Sep 2025 | INR 1.00/share final dividend for FY2025 | Capital return | Paid c. 30 Oct 2025 |
| 31 Dec 2025 | Sale of 520,000 Shri Tulsi Phosphate shares to promoter | Portfolio rationalisation | Completed; associate status ended |
| 17 Mar 2026 | RCF marketing & distribution MoU for SSP (to 01 Jun 2027) | Channel partnership | Active |
| 31 Mar 2026 | Bank facilities restructured: one bank's limits withdrawn on no-dues; new INR 12 Cr LT/ST facility rated | Financing | Completed |
| 08 Sep 2026 | Acuité rating BBB-/A3 on enhanced INR 51.75 Cr facilities | Financing | Completed (possibly to support larger working-capital lines) |
| 2,026 | Board refresh: new ID (Sakina Dharwala), committee reconstitution | Governance | Completed |
ESG / sustainability commitments, cost programmes, guidance
| Item | Status |
|---|---|
| Emissions or net-zero targets | — |
| Cost-reduction programmes with targets | — |
| Medium-term financial targets / guidance | None issued |
| Capacity expansion plans | None announced (contrast: Rama, Madhya Bharat and Khaitan all have announced SSP/acid expansions) |
CARE's rating sensitivities provide the only quasi-targets: an upgrade would need sustained total operating income above INR 130 Cr with PBILDT margin of 8%, gearing below 0.5x, interest coverage above 5x and total debt/GCA below 5x. FY2026 met the revenue and margin thresholds but not the coverage threshold (≈4.2x).
Products & Services
All products sit in the single Fertilisers segment. Pricing for subsidised products (SSP, NPK) follows MRP plus NBS subsidy; product-level prices are not disclosed by the company.
Manufactured products
| Product | Description & specifications | Target customer | Launch / latest year | Pricing model | Flagship brand(s) |
|---|---|---|---|---|---|
| Single Super Phosphate (SSP) | Phosphatic fertiliser made by acidulating rock phosphate with sulphuric acid; delivers water-soluble P2O5 (~16% standard grade) plus sulphur and calcium. Produced at both Dewas and Meghnagar (combined 160,000 MTPA). Variants are made for institutional marketers | Farmers via dealers; bulk off-take by IPL, HURL, RCF, Matix, MAIDC, BVFCL | Since inception (exact year not disclosed) | MRP + NBS subsidy (government-notified per-tonne rate) | "Smriddhi" (company's SSP brand per Musaffa/company data); "Krishi Samridhi" (variant marketed by Matix in West Bengal and MAIDC in Maharashtra) |
| NPK mixtures | Nitrogen-phosphorus-potassium compound/mixed fertilisers | Farmers; IPL marketing arrangement for 25,000 MTPA in MP and Chhattisgarh | — | MRP + NBS subsidy (where notified) | — |
| Zinc Sulphate | Micronutrient fertiliser to correct zinc deficiency | Farmers (paddy, wheat, maize belts) | — | Market-priced (non-subsidised) | — |
| Phosphate Rich Organic Manure (PROM) | Organic manure enriched with rock phosphate; FCO-notified | Organic/low-cost input buyers | — | Market-priced; Market Development Assistance eligibility not disclosed | — |
| Potash Derived from Molasses (PDM) | Potassic fertiliser (K2O 14.5%) made from distillery spent-wash ash; raw material supplied under MoU with Som Distilleries; company described as the leading MP producer at launch | Farmers seeking cheaper potash substitute | c. 2019 (licence from MP Farmer Welfare & Agriculture Development Dept.) | NBS-eligible (PDM is in the NBS list) | — |
| Organic manure | General organic manure | Farmers | — | Market-priced | — |
| Calcium Sulphate (soil conditioner / gypsum) | Soil amendment for sodic soils and sulphur/calcium supply; by-product synergy with SSP | Farmers | — | Market-priced | — |
Traded products
| Product | Description | Basis |
|---|---|---|
| Di-Ammonium Phosphate (DAP) | Traded opportunistically per customer demand | Company profile; CARE |
| Urea | Traded opportunistically | Company profile; CARE |
| Ammonium Sulphate | Traded opportunistically | Company profile; CARE |
| Other fertilisers / commodities | Historically commodity trading ("Others") | Older segment descriptions |
Services
None. The in-house testing laboratory is a quality-control facility, not a commercial service.
Institutional supply/marketing agreements (portfolio channels)
| Counterparty | Product | Volume | Term | Geography |
|---|---|---|---|---|
| Indian Potash Ltd | SSP | Minimum 40,000 MTPA ±10% | Long-standing (dates not disclosed) | MP, Chhattisgarh, Maharashtra |
| Indian Potash Ltd | NPK | 25,000 MTPA | Long-standing | MP, Chhattisgarh |
| Matix Fertilisers & Chemicals | SSP variant ("Krishi Samridhi") | Minimum 60,000 MTPA | Rolling; latest disclosed 17 Apr 2024 – 31 Mar 2025 | West Bengal |
| HURL | SSP | 125,350 MT | 28 May 2024 – 27 May 2025 | — |
| RCF | SSP | — | 17 Mar 2026 – 01 Jun 2027 | RCF network |
| MAIDC | SSP ("Krishi Samridhi") | 25,227 t | From 01 Mar 2023 | Maharashtra |
| BVFCL | SSP | 25,000 t | From 12 Jan 2023 | North-East (BVFCL network) |
Financial Narrative
Basis: Standalone, INR Cr, FY ending 31 March. FY2022–FY2025 from CMOTS standalone P&L (Arihant Capital) and CARE; FY2026 from the four quarterly standalone results filed on NSE (summed, via Screener.in) cross-checked with Anand Rathi. Gross profit is computed as net sales minus raw materials consumed adjusted for inventory change (CMOTS line items); it is not a company-reported line.
Income statement
Notes: FY2024 EPS per Screener standalone (–3.77); TipRanks consolidated shows –2.60. FY2026 DPS: no dividend for FY2026 appears in exchange data reviewed (Screener shows 0% payout and 0% yield); not confirmed by the annual report text — treat as "no dividend declared, unconfirmed". FY2026 tax derived as PBT less PAT.
Margins and growth
Commentary. Revenue nearly doubled in FY2022 (INR 59.98 Cr → 116.06 Cr) as global phosphate prices spiked and the government raised NBS rates, inflating SSP realisations. FY2023 extended the high-price year to a revenue peak of INR 131 Cr. FY2024 was the inflection downward: the subsidy budget was cut as raw-material prices eased, rainfall was deficient in key markets (the FY2024 Directors' Report attributes lower results to reduced subsidy allocation and inadequate rainfall), and the company was left with high-cost inventory against falling realisations, producing a standalone operating loss of about INR 6 Cr and a net loss of INR 7.65 Cr — including two consecutive loss quarters (Dec-2023, Mar-2024). FY2025 brought recovery, driven per CARE by higher subsidy rates and ~5% higher manufacturing volume, with EBITDA margin rebounding to 11.7%. FY2026 delivered record revenue of INR 147.95 Cr (+23%) on the back of Kharif 2025 subsidy increases for SSP (industry sources cite an SSP NBS rate of about INR 7,263/MT for Kharif 2025) and DAP shortages that shifted farmers toward SSP. However, the year was front-loaded: standalone EBITDA margin was 19.9% in Q1 FY2026 but fell steadily to 9.5%, 7.8% and 6.1% in Q2–Q4, and Q1 FY2027 revenue fell 27% YoY to INR 28.92 Cr with PAT down 69% to INR 1.32 Cr. Finance costs have more than doubled since FY2022 (1.67 → 3.95 Cr), reflecting higher working-capital borrowing.
Quarterly trajectory (standalone, INR Cr)
Source: Screener.in, compiled from NSE quarterly standalone filings. Consolidated Q4 FY2026 showed a net loss of about INR 0.29 Cr (Kotak Neo), versus standalone profit of INR 1.02 Cr.
Balance sheet (standalone, INR Cr; Screener figures rounded to whole crore)
Notes: (a) Cash FY2025 is CARE's "free cash and bank balance" (INR 0.10 Cr); FY2026 cash INR 22.31 million from StockAnalysis. (b) Debt split: CARE describes facilities as fund-based cash credit (INR 17.75 Cr LT-rated CC), LT/ST fund/non-fund (INR 12 Cr) and LC (INR 16 Cr), with scheduled term-debt repayment of only INR 0.23 Cr in FY2026 — i.e., borrowings are overwhelmingly working-capital; precise ST/LT split not disclosed. (c) Reserves rising in FY2024 despite a net loss is anomalous in the aggregated data and could reflect OCI/revaluation or data rounding; not verifiable from sources reviewed. (d) CARE's overall gearing (0.54x FY2024; 0.65x FY2025) implies a broader debt definition (likely including LC-backed acceptances) and/or adjusted net worth versus Screener's ~0.44x. (e) No goodwill or intangibles disclosed. (f) Book value per share INR 34.8 (Screener, Oct 2026).
Cash flow (standalone, INR Cr)
Dividends paid derived as DPS × 20.27 million shares (FY2022 interim INR 0.25; FY2026 cash outflow for FY2025 final INR 1.00 paid c. 30 Oct 2025). No buyback has ever been announced.
Ratios
Sources: Screener.in (ROCE, D/E inputs, day-counts); CARE (gearing, coverage); current ratio from StockAnalysis (latest). ROIC is not publicly disclosed. CARE separately measured the operating cycle at 135 days (FY2025) vs 132 days (FY2024) and total debt / gross cash accruals at 4.48x for FY2025, with GCA of INR 9.32 Cr (FY2025) versus a cash loss of INR 8.77 Cr (FY2024).
Ratio commentary. Returns are adequate in good years (ROE 12–13%) but negative in bad ones, giving a weak through-cycle average (Screener: 3-year ROE ≈ 3%, 5-year ≈ 6%). The single most important balance-sheet dynamic is inventory: inventory days swung from 145 (FY2022) to 291 (FY2025) as the company stocked imported rock phosphate and finished SSP ahead of seasons, funded partly by supplier credit (payable days 227 in FY2025) and partly by bank lines that CARE describes as almost fully utilised over the 12 months to February 2026. FY2026 improved the cash cycle to 93 days. Leverage is moderate in absolute terms (net debt ≈ 1.7x EBITDA), but liquidity is thin: CARE characterises liquidity as "stretched", with negligible free cash and near-full use of working-capital limits.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue / net sales | 116.06 | 131.02 | 103.82 | 119.88 | 147.95 |
Raw materials consumed adj. for stock change | 79.53 | 89.43 | 80.74 | 75.18 | — |
Gross profit (derived) | 36.53 | 41.59 | 23.08 | 44.70 | — |
EBITDA excl. other income | 8.79 | 10.46 | -5.99 | 13.97 | 16.46 |
Other income | 1.19 | 0.34 | 0.63 | 0.91 | 1.22 |
Depreciation | 1.23 | 1.56 | 1.73 | 1.95 | 1.96 |
Operating income (EBIT excl. OI) | 7.56 | 8.90 | -7.72 | 12.02 | 14.50 |
Interest / finance cost | 1.67 | 2.13 | 3.41 | 3.83 | 3.95 |
Pre-tax income | 7.08 | 7.11 | -10.50 | 9.10 | 11.77 |
Tax (current + deferred) | 1.24 | 2.10 | -2.85 | 3.84 | 3.60 |
Net income | 5.83 | 5.00 | -7.65 | 5.26 | 8.17 |
EPS basic (INR) | 2.88 | 2.47 | -3.77 | 2.59 | 4.03 |
EPS diluted (INR) | 2.88 | 2.47 | -3.77 | 2.59 | 4.03 |
Dividend per share declared for year (INR) | 0.25 | 0 | 0 | 1.00 | 0 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (derived) | 31.5 | 31.7 | 22.2 | 37.3 | — |
EBITDA margin (excl. OI) | 7.6 | 8.0 | -5.8 | 11.7 | 11.1 |
Operating (EBIT) margin | 6.5 | 6.8 | -7.4 | 10.0 | 9.8 |
Pre-tax margin | 6.1 | 5.4 | -10.1 | 7.6 | 8.0 |
Net margin | 5.0 | 3.8 | -7.4 | 4.4 | 5.5 |
Revenue growth YoY | 93.5 | 12.9 | -20.8 | 15.5 | 23.4 |
CAGR metric | Value | Basis | — | — | — |
Revenue CAGR FY2022–FY2026 (4 yrs) | ≈ 6.3% | 116.06 → 147.95 | — | — | — |
Revenue CAGR FY2021–FY2026 (5 yrs) | ≈ 19.8% | 59.98 → 147.95 (Screener reports 20%) | — | — | — |
10-year sales CAGR | 7% | Screener.in | — | — | — |
5-year profit CAGR | 20% | Screener.in | — | — | — |
Income Statement and Margin Analysis (%)
| Metric (INR Cr) | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Sales | 23.92 | 31.50 | 22.81 | 30.11 | 39.80 | 40.08 | 35.84 | 32.23 | 28.92 |
Operating profit | -1.80 | 3.17 | 4.18 | 3.90 | 7.93 | 3.79 | 2.79 | 1.95 | 3.16 |
OPM (%) | -7.5 | 10.1 | 18.3 | 13.0 | 19.9 | 9.5 | 7.8 | 6.1 | 10.9 |
PBT | 0.05 | 3.60 | 2.79 | 2.65 | 6.39 | 2.37 | 1.48 | 1.53 | 1.80 |
Net profit | -0.19 | 0.44 | 2.49 | 2.51 | 4.29 | 2.01 | 0.85 | 1.02 | 1.32 |
EPS (INR) | -0.09 | 0.22 | 1.23 | 1.24 | 2.12 | 0.99 | 0.42 | 0.50 | 0.65 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 85 | 130 | 109 | 157 | 154 |
Net fixed assets | 21 | 22 | 24 | 23 | 21 |
Capital work-in-progress | 1 | 3 | 0 | 0 | 0 |
Investments | 1 | 0 | 5 | 5 | 5 |
Other assets (inventory, receivables incl. subsidy, cash) | 62 | 105 | 80 | 129 | 127 |
Cash & equivalents | — | — | — | 0.10 | 2.23 |
Total debt | 13 | 27 | 29 | 28 | 30 |
Net debt (approx.) | — | — | — | 28 | 28 |
Equity share capital | 20 | 20 | 20 | 20 | 20 |
Reserves | 27 | 32 | 39 | 44 | 50 |
Total equity | 47 | 52 | 59 | 64 | 70 |
Goodwill & intangibles | 0 | 0 | 0 | 0 | 0 |
Other liabilities (payables, provisions) | 25 | 51 | 21 | 64 | 53 |
Working capital proxy (other assets – other liabilities) | 37 | 54 | 59 | 65 | 74 |
Cash Flow
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (Screener) | 14 | -6 | 3 | 3 | 4 |
Operating cash flow (CARE, where disclosed) | — | — | -11.49 | -3.29 | — |
Capital expenditure (derived = CFO – FCF) | 7 | 5 | 2 | 0 | 1 |
Free cash flow (Screener) | 7 | -11 | 1 | 3 | 3 |
Investing cash flow | -10 | -7 | -2 | 0 | -1 |
Financing cash flow | -3 | 12 | -1 | -4 | -3 |
Dividends paid (approx.) | 0.51 | 0 | 0 | 0 | 2.03 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, PAT / avg equity) | 13.2 | 10.1 | -13.8 | 8.6 | 12.2 |
ROA (%, PAT / avg assets) | 7.4 | 4.7 | -6.4 | 4.0 | 5.3 |
ROCE (%, Screener) | 14 | 13 | -9 | 14 | 16 |
Current ratio (x) | — | — | — | — | 1.58 |
Debt / equity (x, Screener basis) | 0.28 | 0.52 | 0.49 | 0.44 | 0.43 |
Overall gearing (x, CARE basis) | — | — | 0.54 | 0.65 | — |
Net debt / EBITDA (x) | 1.5 | 2.6 | — | 2.0 | 1.7 |
Interest coverage (x, EBITDA / interest) | 5.3 | 4.9 | -1.8 | 3.6 | 4.2 |
Interest coverage (x, CARE PBILDT basis) | — | — | — | 3.65 | — |
Asset turnover (x, sales / avg assets) | 1.47 | 1.22 | 0.87 | 0.90 | 0.95 |
Debtor days | 36 | 45 | 44 | 68 | 65 |
Inventory days | 145 | 250 | 154 | 291 | 177 |
Payable days | 84 | 183 | 74 | 227 | 148 |
Cash conversion cycle (days) | 97 | 113 | 124 | 132 | 93 |
Working-capital days | 75 | 78 | 105 | 116 | 109 |
Revenue by Region and Region Margins & Growth (%)
| Region (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India (domestic) | 103.82 | 119.88 | 147.95 |
Outside India | 0 | 0 | 0 |
India YoY growth (%) | -20.8 | 15.5 | 23.4 |
State Details
| State | Channel presence | Notes |
|---|---|---|
Madhya Pradesh | Own dealers; IPL (SSP and NPK) | Home state; both plants located here |
Maharashtra | Own dealers; IPL (SSP); MAIDC (Krishi Samridhi) | Large soybean/cotton SSP market |
Chhattisgarh | Own dealers; IPL (SSP and NPK) | Also home of former associate Shri Tulsi Phosphate |
Rajasthan | Own dealers | Mustard/groundnut SSP market |
Uttar Pradesh | Own dealers | — |
Andhra Pradesh | Own dealers | — |
West Bengal | Matix (Krishi Samridhi variant) | Contract supply |
North-East | BVFCL MoU (2023) | Contract supply |
Capital Markets
| Measure | Value | Source |
|---|---|---|
Last close | INR 22.9 (09 Oct 2026) | Screener.in |
52-week high / low | INR 44.4 / 21.0 | Screener.in |
1-year return | ≈ -45% | Screener.in |
3-year price CAGR | ≈ -16% p.a. | Screener.in |
5-year price CAGR | ≈ +4% p.a. | Screener.in |
IPO price (2016) | INR 22 | NSE/PTI |
Listing-day close (16 Nov 2016) | INR 22.85 | PTI |
Liquidity | Thinly traded (vendor estimates ~INR 5–6 lakh/day) | VestAI |
Valuation Multiples
| Multiple | Agro Phos | Basis |
|---|---|---|
P/E (TTM standalone, PAT ≈ INR 5.20 Cr) | 9.2x | Screener.in |
P/E (FY2026 standalone PAT INR 8.17 Cr) | 5.7x | Derived |
P/B | 0.66x | Screener (BV INR 34.8) |
EV (mkt cap 46.4 + net debt ≈ 27.6) | ≈ INR 74 Cr | Derived |
EV / EBITDA (TTM EBITDA ≈ INR 11.7 Cr) | ≈ 6.3x | Derived |
EV / Sales (TTM sales ≈ INR 137 Cr) | ≈ 0.54x | Derived |
Dividend yield (trailing) | 0% on Screener (FY2026 no dividend); ~4.4% on the INR 1.00 paid Oct 2025 at current price | Screener / derived |
Peer multiple (approx., dates vary) | P/E (x) | Source |
Khaitan Chemicals & Fertilizers | 7.6 | Screener.in (2026) |
Rama Phosphates | ≈ 8.3 (mkt cap ≈ INR 439 Cr / FY2026 PAT INR 52.7 Cr) | Fyers / derived |
Dividend metric (INR per share)
| Dividend metric (INR per share) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend declared for the year | 0.25 | 0 | 0 | 1.00 | 0 |
Payout ratio (% of standalone EPS) | 8.7 | 0 | 0 | 38.6 | 0 |
Ex-date | Type | Amount (INR) | — | — | — |
24 Sep 2018 | Final (FY2018) | 0.05 | — | — | — |
16 Mar 2022 | Interim (FY2022) | 0.25 | — | — | — |
23 Sep 2025 | Final (FY2025) | 1.00 | — | — | — |
Credit Ratings
| Agency | Date | Long-term | Short-term | Facilities (INR Cr) | Outlook |
|---|---|---|---|---|---|
Acuité Ratings & Research | 08 Sep 2026 | ACUITE BBB- (assigned) | ACUITE A3 (assigned) | 33.25 LT + 18.50 ST = 51.75 | Stable |
CARE Ratings | 31 Mar 2026 | CARE BB+ (reaffirmed) | CARE A4+ (reaffirmed) | 17.75 CC + 12.00 LT/ST + 16.00 LC = 45.75 | Stable |
CARE Ratings | 10 Mar 2025 | CARE BB+ | CARE A4+ | — | Stable |
CARE Ratings | 11 Mar 2024 / 23 Feb 2024 | CARE BB+ (downgraded from BBB-) | CARE A4+ (from A3) | — | Stable |
CARE Ratings | 06 Dec 2023 | CARE BBB- | CARE A3 | 10 LT + 6 ST | Stable |
CARE Ratings | 20 Oct 2022 | CARE BBB- (upgraded) | CARE A3 | 10 LT | Stable |
CARE Ratings | 2019–2021 | CARE BB+ | CARE A4+ | 10–17 LT | Stable |
CARE Ratings | 18 Oct 2018 | CARE BB+ (downgraded) | CARE A4+ | — | Stable |
CARE Ratings | 13 Apr 2017 / 02 Apr 2018 | CARE BBB- | CARE A3 | 15 LT + 6 ST | Stable |
Brickwork Ratings | 25 Jul 2024; 16 May 2025 | — | — | — | — |
ICRA | 07 Nov 2014 | Suspended (non-cooperation) | — | — | — |
Analyst Conclusions
Management guidance and consensus
Management does not issue guidance and holds no earnings calls; there is no sell-side consensus. The only forward-looking reference points are CARE's expectation (Mar-2026) of gross cash accruals of ~INR 9.5–10 Cr for FY2026 against negligible term-debt repayments, and its warning that any reduction in NPK subsidy allocation could affect FY2027 revenue and profitability. The Q1 FY2027 print (sales INR 28.92 Cr, –27% YoY; PAT INR 1.32 Cr, –69% YoY) suggests FY2027 is tracking below FY2026's record.
Bull case (3 arguments)
-
Deep value on asset and earnings measures. At ~0.66x book and ~5.7x FY2026 earnings (≈6.3x TTM EV/EBITDA), the stock prices in a return to FY2024-style losses. If the company merely sustains FY2025-type profitability (~INR 5 Cr PAT), the equity is cheap relative to listed peers at 7–8x earnings.
-
Structural tailwinds for SSP. Government preference for SSP as a cost-effective P-and-S source, recurring DAP supply tightness and higher NBS rates (Kharif 2025) underpinned record FY2026 revenue; PSU marketers (RCF to Jun 2027, IPL, HURL) want third-party SSP volume, giving a small producer with spare capacity a route to high utilisation.
-
Credit and governance momentum. A second agency rated the company investment-grade (Acuité BBB-/A3 on INR 51.75 Cr) in September 2026, enhanced bank lines could relieve the working-capital bottleneck, the board now has four independents including two women, and the associate exit simplifies the reporting structure.
Bear case (3 arguments)
-
Earnings already rolling over. Quarterly operating margin fell from 19.9% to 6.1% across FY2026 and Q1 FY2027 profit fell 69% YoY; with the subsidy budget trending down (INR 1.88 → 1.68 lakh Cr over FY2024–26), FY2026 may prove a cyclical peak.
-
Competitive squeeze from integrated giants. Madhya Bharat (Dhule 330,000 MT SSP), Rama (Udaipur +65,000 MT; Dhule 216,000 MTPA greenfield) and Khaitan are adding acid-integrated capacity in Agro Phos's core markets; a non-integrated 160,000 MTPA producer has structurally higher costs and no pricing power.
-
Liquidity and governance discount persists. CARE judges liquidity "stretched" with near-fully drawn lines and negative CFO in FY2024–25; the related-party sale of associate shares to the promoter, the stop-start independent-director re-appointment, the NSE results clarification and nil institutional ownership justify a persistent valuation discount.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Expected timing |
|---|---|---|
| Rabi 2026-27 and Kharif 2027 NBS rates for SSP | Primary driver of realisations and margins | Oct 2026; Mar–Apr 2027 |
| Q2 FY2027 results | Test of whether H1 FY2027 decline is seasonal or structural | ~Nov 2026 (StockAnalysis estimates 12 Nov 2026) |
| Operating cash flow and debtor/inventory days | Liquidity stress indicator; CARE downgrade trigger if subsidy delays worsen | Half-yearly / FY2027 annual |
| RCF MoU volumes and renewal of IPL/HURL/Matix arrangements | Volume visibility for 160,000 MTPA capacity | Through Jun 2027 |
| CARE annual review (due ~Mar 2027) vs Acuité BBB- | Convergence or divergence of ratings | Q4 FY2027 |
| Any new acquisition or capacity plan | Only route to scale; previous attempt failed | Ad hoc |
| Dividend decision for FY2026/FY2027 | Signal of cash confidence | AGM Sep 2027 |
| Related-party transactions and board stability | Governance discount | Ongoing |
| Monsoon 2027 forecast (IMD, Apr 2027) | Kharif demand | Apr–Jun 2027 |
Concluding analyst verdict
Agro Phos (India) Limited is an honest but structurally limited business: a two-plant, 160,000 MTPA Single Super Phosphate converter in Madhya Pradesh whose profits are set in New Delhi (through NBS subsidy rates), in Casablanca and Amman (through rock-phosphate prices), and by the monsoon. FY2026 showed the business at its best — record revenue of INR 147.95 Cr, standalone net profit of roughly INR 8.2 Cr, a 12% ROE and an improved 93-day cash cycle — helped by restored SSP subsidy rates and DAP shortages. Yet the same year exposed the fragility: margins slid every quarter from Q1 to Q4, consolidated Q4 was loss-making, and Q1 FY2027 profit fell by more than two-thirds.
The balance sheet is not over-levered (net debt ≈ 1.7x EBITDA), but liquidity is tight and depends on bank lines and timely subsidy receipts. Strategically, the company has opted to be a capacity provider to national marketers (IPL, HURL, RCF) rather than a branded player, which secures volume but forfeits pricing power at the very moment integrated peers are adding hundreds of thousands of tonnes of acid-integrated SSP capacity in its backyard. The failed Bharat Phosphates acquisition removes the only visible growth lever, and governance — combined Chair/MD, promoter-sibling executives, a related-party share sale to the promoter and director-appointment churn — merits a discount.
At ~0.66x book and mid-single-digit earnings multiples, the market already discounts much of this; the stock trades near its 2016 IPO price. For investors, Agro Phos is a high-beta call on SSP subsidy policy rather than a compounding franchise. A constructive stance requires evidence of sustained positive operating cash flow, stable 10%+ operating margins through a full Kharif–Rabi cycle, and a credible capacity or integration plan. Absent these, the verdict is neutral with a negative bias: cheap, but cheap for identifiable reasons.
Source list (primary first): NSE corporate filings for AGROPHOS — results outcomes 14-Nov-2025 and 14-Feb-2026; integrated filing Q2 FY2026; Reg. 30 intimations dated 16-Jul-2025, 26-Feb-2026, 17-Mar-2026, 29-May-2026, 08-Sep-2026; record-date filing 06-Sep-2025; resignation filings 02-Sep-2024 and 29-May-2025; board outcome 17-Jan-2025; annual-report cover letters FY2023-24 and FY2025-26; AGM proceedings 2022. CARE Ratings press releases (13-Apr-2017; 02-Apr-2018; 18-Oct-2018; 03-Apr-2019; 23-Aug-2019; 29-Sep-2020; 17-Aug-2021; 20-Oct-2022; 06-Dec-2023; 31-Mar-2026). NSE Indices press release 06-Mar-2019. Business Standard/PTI, 16-Nov-2016. Aggregators reproducing filings: Screener.in; Arihant Capital/CMOTS; Anand Rathi; Kotak Neo; StockAnalysis; Simply Wall St; TipRanks; 5paisa; Chittorgarh; IIFL; DSIJ. Peer data: Rama Phosphates, Madhya Bharat Agro Products and Khaitan Chemicals & Fertilizers FY2026 results coverage (Capital Market, Free Press Journal, ScanX, StockAnalysis) and their NSE investor presentations.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title / category | Tenure / key dates | Prior roles & background | Education | Age |
|---|---|---|---|---|---|
Raj Kumar Gupta (DIN 00244925) | Chairman & Managing Director; Promoter | Co-founder (2001); MD re-appointed for 3 years in Sept 2022 and again by Board on 17 Jan 2025 | Over two decades in fertiliser industry (CARE); oversees overall business | B.Sc. | 50 (as of Jan 2025 disclosure) |
Vishnu Kant Gupta (DIN 05233476) | Whole-time Director; Chief Financial Officer (per vendor profile); Promoter | WTD re-appointed by Board 17 Jan 2025 | ~10 years in fertiliser industry; looks after production (CARE). Brother of Raj Kumar Gupta | — | — |
Abhishek Kalekar | Non-Executive, Non-Independent Director | On board since at least 2022 | Holds 150,000 shares (0.74%) | — | — |
Mahesh Kumar Agarwal | Independent Director | On board since at least FY2024 | — | — | — |
Maya Vishwakarma | Independent Director; Chairperson of Audit and other committees from 26 Feb 2026 | — | — | — | — |
Chandresh Kumar Gupta (DIN 09042779) | Independent Director | First term ended 24 Jan 2026 (ceased); re-appointment proposal of 14 Feb 2026 withdrawn 26 Feb 2026; members approved re-appointment for five years from 30 Sep 2026 | — | — | — |
Sakina Dharwala | Independent Director | Appointed for five years from 11 Jul 2026; regularised at 30 Sep 2026 AGM | — | — | — |
Reena Saluja | Company Secretary & Compliance Officer (KMP) | In role since at least 2024 | ICSI member A55665 | CS | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Attribute | Status |
|---|---|
Board size | 7 (2 executive promoter directors, 1 non-executive non-independent, 4 independent) as of Oct 2026 |
Independence | 4 of 7 independent (~57%) after Sakina Dharwala's appointment and Chandresh Kumar Gupta's re-appointment |
Women directors | 2 (Maya Vishwakarma, Sakina Dharwala) |
Chair / CEO separation | Not separated — Raj Kumar Gupta is both Chairman and MD |
Family relationships | Raj Kumar Gupta and Vishnu Kant Gupta are brothers (per Jan-2025 disclosure) |
Audit Committee (post 26 Feb 2026) | Maya Vishwakarma (Chair, ID), Mahesh Kumar Agarwal (ID), Abhishek Kalekar (NED) |
Nomination & Remuneration Committee (post 26 Feb 2026) | Maya Vishwakarma (Chair), Mahesh Kumar Agarwal, Abhishek Kalekar |
Stakeholders' Relationship / CSR Committee | Raj Kumar Gupta (Chair), Vishnu Kant Gupta, Maya Vishwakarma (composition per 26 Feb 2026 filing) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
02 Sep 2024 | Tushar Dave (ID) resigned | Cited pre-occupation and personal commitments |
17 Jan 2025 | MD and WTD re-appointed; EGM called | Routine re-appointment |
29 May 2025 | Shweta Bhamare (ID) resigned | Cited pre-occupation |
14 Feb 2026 | Board proposed second term for Chandresh Kumar Gupta as additional ID | Subject to shareholder approval |
26 Feb 2026 | Proposal withdrawn; Chandresh Kumar Gupta ceased (first term ended 24 Jan 2026); committees reconstituted | Reason for withdrawal not disclosed; note he had technically completed his term a month before the proposal |
11 Jul 2026 | Sakina Dharwala appointed ID | Board refresh |
30 Sep 2026 | Members approved Chandresh Kumar Gupta's re-appointment as ID for five years | Reversal of February withdrawal |
Major Shareholders
| Holder category | % (Jun 2026) |
|---|---|
Promoters & promoter group | 54.27 |
Foreign institutional investors | 0.00 |
Domestic institutional investors | 0.00 |
Public / retail & others | 45.73 |
Number of shareholders | 18,650 |
Named holder | Shares |
Raj Kumar Gupta (promoter) | 4,708,895 |
Vishnu Kant Gupta (promoter) | 2,337,985 |
Ramesh Suhane | 1,795,050 |
Abhishek Kalekar (director) | 150,000 |
Other promoter-group members | balance to 54.27% |
Competitive Landscape
Key Competitors
| # | Competitor | Listing | Positioning vs Agro Phos | FY2026 revenue (INR Cr) | Notes |
|---|---|---|---|---|---|
| 1 | Khaitan Chemicals & Fertilizers | NSE/BSE | Largest or second-largest SSP producer; ~10% national SSP share; six units incl. Nimrani (MP) 400,000 MT; acid integration | ≈ 1,003 | FY2026 PAT INR 68.76 Cr; produced 440,271 MT SSP |
| 2 | Madhya Bharat Agro Products (Ostwal Group) | NSE/BSE | Sagar (MP) neighbour; SSP 240,000 MT + DAP/NPK 240,000 MT; Dhule (MH) SSP 330,000 MT; full acid/BRP integration | ≈ 1,867 | FY2026 PAT INR 150.18 Cr; SSP utilisation 98% |
| 3 | Rama Phosphates | NSE/BSE | SSP 914,000 MT → 979,000 MT after Udaipur expansion; greenfield Dhule SSP; soya segment | ≈ 893 | FY2026 PAT INR 52.71 Cr |
| 4 | Coromandel International | NSE/BSE | India's largest private phosphatic player with major SSP footprint | Not compiled (multi-thousand-crore scale) | — |
| 5 | Shri Tulsi Phosphate Ltd | Unlisted | Chhattisgarh; Agro Phos holds 19.51% | — | Former associate |
| 6 | Bharat Phosphates & Chemicals Pvt. Ltd. | Unlisted | Former acquisition target | — | — |
| 7 | Bohra Industries | Listed (SME) | Rajasthan SSP producer | — | Named as peer by Zerodha/Tickertape |
| 8 | Phosphate Company Ltd | Listed | West Bengal SSP producer | — | Named peer |
| 9 | Teesta Agro Industries | Listed | West Bengal SSP/fertiliser producer | — | Named peer |
| 10 | Basant Agro Tech (India) | Listed | Akola (MH) SSP and NPK mixtures | — | Named peer |
| 11 | Shiva Global Agro Industries | Listed | Nanded (MH) SSP/mixtures | — | Named peer |
| 12 | Indian Phosphate Ltd / Bharat Agri Fert & Realty / Saptak Chem & Business | Listed | Small SSP-related players | — | Named peers on broker pages |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Agro Phos | Madhya Bharat Agro | Khaitan Chemicals | Rama Phosphates |
|---|---|---|---|---|
Revenue (INR Cr) | 147.95 | 1,866.98 | 1,003.1 | 893.04 |
Revenue growth YoY (%) | 23.4 | 76.3 | 39.1 | 20.1 |
Net profit (INR Cr) | 8.17 | 150.18 | 68.76 | 52.71 |
Net margin (%) | 5.5 | 8.0 | 6.9 | 5.9 |
EBITDA / operating margin (%) | 11.1 | — | 10.6 (operating income / revenue) | 8.8 (operating income / revenue) |
SSP capacity (MTPA) | 160,000 | 570,000 | ~1100000 (sum of disclosed unit LACs, approx.) | 914,000 |
Acid / backward integration | No | Yes (SA, PA, BRP) | Yes (SA) | Yes (SA) |



